Shareholders Alerted of Potential Losses on Investment in ImmunityBio, by Pomerantz Law Firm

August 15, 2023

Categories: BiotechnologyTags: , , Views: 62

🌧️Trending News

IMMUNITYBIO ($NASDAQ:IBRX): Pomerantz LLP is alerting shareholders of ImmunityBio, Inc. that a class action lawsuit has been filed against the company for potential losses on investments. The suit has been filed in the U.S. District Court for the Central District of California. ImmunityBio, Inc. is a clinical-stage biotechnology company specializing in the development of immunotherapies for various cancers, inflammatory and infectious diseases. The company is focused on developing next-generation CAR-T (Chimeric Antigen Receptor T-Cell) therapies, which are engineered immune cells that recognize and attack tumors.

Additionally, ImmunityBio is also engaged in the development of natural killer cell therapies, which are designed to stimulate the body’s immune system to fight cancer and other disease. ImmunityBio’s therapies are designed to be safer and more effective than existing treatments, with the potential to treat a broad range of diseases.

Share Price

While the stock has seen an increase in value, shareholders may face losses due to ImmunityBio, Inc.’s alleged violations of the federal securities laws. Pomerantz Law Firm is currently investigating the claims on behalf of IMMUNITYBIO stockholders and is urging investors to contact them for more information about the current situation. Live Quote…

About the Company

  • ImmunityBio_by_Pomerantz_Law_Firm”>Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Immunitybio. ImmunityBio_by_Pomerantz_Law_Firm”>More…

    Total Revenues Net Income Net Margin
    0.59 -473.38 -82628.4%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Immunitybio. ImmunityBio_by_Pomerantz_Law_Firm”>More…

    Operations Investing Financing
    -335.41 -37.15 354.23
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Immunitybio. ImmunityBio_by_Pomerantz_Law_Firm”>More…

    Total Assets Total Liabilities Book Value Per Share
    291.23 936.41 -1.47
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Immunitybio are shown below. ImmunityBio_by_Pomerantz_Law_Firm”>More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    -52.2% -61971.6%
    FCF Margin ROE ROA
    -65410.5% 39.2% -78.7%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    GoodWhale has conducted a comprehensive analysis of IMMUNITYBIO, and our overall risk rating for this company is medium. This is based on our assessment of the financial and business fundamentals of the company. We have identified three risk warnings in the balance sheet, cash flow statement and financial journal. These risk warnings are indications that the company may be more vulnerable to unexpected changes in the market or financial environment than previously thought. If you would like to find out more about these warnings, please become a registered user of GoodWhale. Ultimately, we believe that IMMUNITYBIO is a potentially viable investment, but it is important to conduct thorough due diligence before committing any funds to this venture. We at GoodWhale are confident that our analysis will provide you with the necessary insights to make an informed decision. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    The biotech industry is fiercely competitive, and ImmunityBio Inc is up against some stiff competition. Its main competitors are Sensei Biotherapeutics Inc, Caribou Biosciences Inc, and Bolt Biotherapeutics Inc. All of these companies are vying for a piece of the pie in the immunotherapy market, and each has its own unique approach to treatment. ImmunityBio Inc has a strong track record and is well-positioned to continue its success in the face of stiff competition.

    – Sensei Biotherapeutics Inc ($NASDAQ:SNSE)

    In 2022, Sensei Biotherapeutics Inc had a market cap of 44.85M and a Return on Equity of -31.43%. The company is engaged in the research, development and commercialization of cancer immunotherapy products. Its products are designed to harness the power of the immune system to kill cancer cells.

    – Caribou Biosciences Inc ($NASDAQ:CRBU)

    Caribou Biosciences Inc is a leading edge biotechnology company that is focused on developing innovative CRISPR-based gene editing tools and therapeutics. The company has a market cap of 571.3M as of 2022 and a return on equity of -24.1%. Caribou’s mission is to empower the scientific community to cure disease and improve our quality of life. The company’s products are based on its proprietary CRISPR-Cas9 technology, which is a powerful tool for genome editing. Caribou’s products are used by scientists around the world to study a wide range of diseases and to develop new therapeutics. Caribou is headquartered in Berkeley, California.

    – Bolt Biotherapeutics Inc ($NASDAQ:BOLT)

    Bolt Biotherapeutics Inc is a clinical stage immuno-oncology company. The company is engaged in developing immunotherapies based on its Antibody-Oligonucleotide Conjugates (AOCs) platform. The company’s lead product candidate is BTA-A1, an AOC targeting antigens expressed in a variety of solid tumors. The company is also developing other product candidates, including BT-A02, BT-A03 and BT-A04, which are in preclinical development.

    As of 2022, Bolt Biotherapeutics Inc has a market cap of 54.58M and a Return on Equity of -44.7%. The company’s lead product candidate, BTA-A1, is currently in clinical development. The company is also developing other product candidates which are in preclinical development.


    Investors in ImmunityBio, Inc. may be eligible to recover losses in a class action lawsuit. The lawsuit is based on allegations of the company’s mismanagement and failure to adhere to federal securities laws. The complaint alleges that ImmunityBio misled shareholders by hiding information about their financial performance and investments, and artificially inflated stock prices.

    Recent Posts

    Leave a Comment